Serum CXCL10 and CRP Levels in Patients with Acne Vulgaris in Correlation with Disease Severity (CXCL10)

March 7, 2025 updated by: Dina Essam, Assiut University
the correlations between CXCL10 levels, CRP, and acne severity scores (e.g., Global Acne Grading System) suggest that CXCL10 could serve as a biomarker of inflammation and acne severity. Understanding the relationship between CXCL10, CRP, and acne severity may offer insights into novel therapeutic strategies targeting inflammatory pathways in acne.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Cross-sectional Observational Study. using 4 groups a 3 of different acne severity and controle one . the serum cxcl10 and crp will measured in each patient to correlate with disease severity

Study Type

Observational

Enrollment (Estimated)

88

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
      • Assiut, Egypt, 71515
        • Assiut University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

the patients with acne with different severity

Description

Inclusion Criteria:

  1. Patients aged 12-40 years diagnosed with acne vulgaris.
  2. Both genders included.
  3. Patients with mild, moderate, or severe acne severity as determined by a validated scoring system (e.g., Global Acne Grading System).
  4. Patients not on systemic acne treatment (e.g., isotretinoin or antibiotics) or anti-inflammatory drugs.

Exclusion Criteria:

  1. Patients with autoimmune diseases, systemic illnesses, acute infection or any other chronic inflammatory conditions that may affect CRP or CXCL10 levels.
  2. Pregnant or lactating individuals.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
mild acne group
mild disease severity
Diagnostic test: serum cxcl10
serum blood sample to measure the cxcl10
Diagnostic test: serum crp
blood sample to measure crp
moderate acne group
moderate disease severity
Diagnostic test: serum cxcl10
serum blood sample to measure the cxcl10
Diagnostic test: serum crp
blood sample to measure crp
severe acne group
severe disease severity
Diagnostic test: serum cxcl10
serum blood sample to measure the cxcl10
Diagnostic test: serum crp
blood sample to measure crp
control group
healthy people
Diagnostic test: serum cxcl10
serum blood sample to measure the cxcl10
Diagnostic test: serum crp
blood sample to measure crp

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation of CXCL10 and CRP levels with acne severity (GAG score).
Time Frame: within one year after the result
compare the result of serum cxcl10 and crp with disease severity
within one year after the result

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identify thresholds of CXCL10 and CRP for predicting moderate/severe acne
Time Frame: within one year after the result
the least result to identify the group
within one year after the result
Explore potential differences based on sex or age groups
Time Frame: within one year of the result
the effect of age and sex on the result
within one year of the result

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Study Director: Doaa Samir, prof, Assiut University
  • Study Director: Ahmed Shawky, prof, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 10, 2025

Primary Completion (Estimated)

March 10, 2026

Study Completion (Estimated)

April 10, 2026

Study Registration Dates

First Submitted

March 4, 2025

First Submitted That Met QC Criteria

March 7, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 7, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • role of CXCL10 and CRP in acne

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acne Vulgaris

Clinical Trials on serum cxcl10

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe